Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen vs Aspirin in Stable Coronary Heart Disease
NCT04308551Withdrawn
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
01
Overview
Randomised, single-blind trial of Indobufen in coronary heart disease (CHD) (2 arms), sponsored by Henan Institute of Cardiovascular Epidemiology. Primary endpoints: Arachidonic acid and Adenosine diphosphate-induced platelet aggregation rates at 90 days and Concentration of Thromboxane B2 (TXB2) at 90 days. Planned start Dec 2024; status: withdrawn.
02
Drugs
Indobufen
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT04308551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308551.